Other news 05/13/2019 Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment. By JLABS Read full story
Other news 03/21/2019 Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment By JLABS Read full story